H.R. 8260: Cardiovascular Disease Early Detection and Prevention Act of 2026

This bill, known as the Cardiovascular Disease Early Detection and Prevention Act of 2026, proposes several changes to health care coverage regarding cardiovascular testing. Its main objective is to require health plans and programs to cover specific cardiovascular tests without any cost-sharing responsibilities for patients.

Overview of Key Provisions

• The bill calls for the coverage of lipoprotein(a) and apolipoprotein B testing for individuals identified as having a greater risk of cardiovascular disease. This includes people with:
  • A family history of premature cardiovascular disease
  • A personal history of heart attack or stroke
  • High levels of LDL cholesterol
  • A diagnosis of diabetes or obesity
  • Other recognized cardiovascular risk factors
• It amends existing laws to ensure that these tests are covered under group health plans and individual health insurance policies, as well as the Medicare and Medicaid programs, without any cost-sharing.
• Specifically, the bill would require that:
  • The Public Health Service Act be amended to mandate coverage for the specified tests without cost-sharing.
  • The Social Security Act be amended to ensure that Medicare and Medicaid also cover these tests without beneficiary co-pays or deductibles.

Health Insurance Plans Implications

All group health plans and individual health insurance policies will be required to include coverage for these tests. Consequently, patients who fall into the high-risk categories outlined above will have access to necessary testing without facing out-of-pocket costs. This aims to facilitate earlier detection and better management of cardiovascular disease, which remains a leading cause of death in the U.S.

Implementation Timeline

The changes mandated by the bill are set to take effect with respect to:

• New health plans starting 180 days after the bill becomes law
• Medicare and Medicaid policies effective on or after the enactment date

Motivation behind the Bill

The motivation for this legislation comes from findings that many standard cholesterol tests do not adequately identify risks for cardiovascular disease, leading to significant health issues. With cardiovascular disease identified as the leading cause of death in the U.S., the bill aims to enhance preventive measures through accurate testing available to at-risk individuals.

Relevant Companies

• ABT (Abbott Laboratories): Abbott could see an increase in demand for its cardiovascular testing products as more people seek suitable screenings as a result of this legislation.
• UNH (UnitedHealth Group): As a major health insurance provider, UnitedHealth will need to adjust its coverage policies to comply with the requirements of the bill, potentially affecting its pricing model.
• DHR (Danaher Corporation): Danaher, which manufactures diagnostic products, may experience an uptick in sales due to increased testing requirements for cardiovascular disease.